Cart
sales@molnova.com
Home -
Products -
Others -
Other Targets -
((2-(1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-L-valine
((2-(1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-L-valine
CAS No. 676129-92-3
((2-(1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-L-valine( ——— )
Catalog No. M39563 CAS No. 676129-92-3
Devaleryl Valsartan Impurity is an intermediate in the synthesis of Valsartan.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 10MG | 526 | In Stock |
|
| 25MG | Get Quote | In Stock |
|
| 50MG | Get Quote | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name((2-(1H-tetrazol-5-yl)-[1,1-biphenyl]-4-yl)methyl)-L-valine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDevaleryl Valsartan Impurity is an intermediate in the synthesis of Valsartan.
-
DescriptionDevaleryl Valsartan Impurity is an intermediate in the synthesis of Valsartan.
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number676129-92-3
-
Formula Weight351.4
-
Molecular FormulaC19H21N5O2
-
Purity>98% (HPLC)
-
SolubilityDMSO : 250 mg/mL (711.44 mM; ultraphonic; )
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. A Sampath, et al. Identification and characterization of potential impurities of valsartan, AT1 receptor antagonist. J Pharm Biomed Anal. 2009 Oct 15;50(3):405-12.?
molnova catalog
related products
-
Delphinidin-3-O-ruti...
Delphinidin-3-O-rutinoside chloride has antioxidant activity.
-
Myricetin 3-O-β-D-xy...
Myricetin 3-O-β-D-xylopyranosyl(1-2)-[α-L-rhamnopyranosyl-(1-6)]-β-D-glucopyranoside
-
25-Hydroxycholestero...
25-Hydroxycholesterol is a steroid derivative that suppresses the cleavage of sterol regulatory element binding proteins (SREBPs).
